Aprea Therapeutics, Inc. Research and Development Expense
Aprea Therapeutics, Inc. (APRE) reported Research and Development Expense of $4.09 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-05-16
- Aprea Therapeutics, Inc. research and development expense for the quarter ending 2022-03-31 was $4.09M, a 39.54% decline year-over-year.
- Aprea Therapeutics, Inc. research and development expense for the quarter ending 2021-12-31 was $4.46M, a 52.16% decline year-over-year.
- Aprea Therapeutics, Inc. research and development expense for the quarter ending 2021-09-30 was $6.02M, a 31.34% decline year-over-year.
- Aprea Therapeutics, Inc. research and development expense for the quarter ending 2021-06-30 was $6.65M, a 37.78% decline year-over-year.
- Aprea Therapeutics, Inc. research and development expense for fiscal 2021 was $23.90M, a 36.92% decline from fiscal 2020.
- Aprea Therapeutics, Inc. research and development expense for fiscal 2020 was $37.88M, a 80.80% increase from fiscal 2019.
- Aprea Therapeutics, Inc. research and development expense for fiscal 2019 was $20.95M, a 47.59% increase from fiscal 2018.
- Aprea Therapeutics, Inc. research and development expense for fiscal 2018 was $14.19M, a 5.99% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-03-31 | $4.09M 10-Q · filed 2022-05-16 | $8.55M derived: sum of 2 quarters · filed 2022-05-16 | $14.57M derived: sum of 3 quarters · filed 2022-05-16 | $21.22M derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-12-31 | $4.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $10.48M derived: sum of 2 quarters · filed 2022-03-15 | $17.13M derived: sum of 3 quarters · filed 2022-03-15 | $23.90M 10-K · filed 2022-03-15 |
| 2021-09-30 | $6.02M 10-Q · filed 2021-11-08 | $12.67M derived: sum of 2 quarters · filed 2021-11-08 | $19.43M 10-Q · filed 2021-11-08 | $28.76M derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-06-30 | $6.65M 10-Q · filed 2021-08-12 | $13.42M 10-Q · filed 2021-08-12 | $22.75M derived: sum of 3 quarters · filed 2022-05-16 | $31.51M derived: sum of 4 quarters · filed 2022-05-16 |
| 2021-03-31 | $6.76M 10-Q · filed 2022-05-16 | $16.09M derived: sum of 2 quarters · filed 2022-05-16 | $24.85M derived: sum of 3 quarters · filed 2022-05-16 | $35.55M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $9.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $18.09M derived: sum of 2 quarters · filed 2022-03-15 | $28.78M derived: sum of 3 quarters · filed 2022-03-15 | $37.88M 10-K · filed 2022-03-15 |
| 2020-09-30 | $8.76M 10-Q · filed 2021-11-08 | $19.46M derived: sum of 2 quarters · filed 2021-11-08 | $28.55M 10-Q · filed 2021-11-08 | $36.59M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-06-30 | $10.69M 10-Q · filed 2021-08-12 | $19.79M 10-Q · filed 2021-08-12 | $27.83M derived: sum of 3 quarters · filed 2022-03-15 | $32.74M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-03-31 | $9.10M 10-Q · filed 2021-05-06 | $17.14M derived: sum of 2 quarters · filed 2022-03-15 | $22.05M derived: sum of 3 quarters · filed 2022-03-15 | $26.37M derived: sum of 4 quarters · filed 2022-03-15 |
| 2019-12-31 | $8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $12.95M derived: sum of 2 quarters · filed 2022-03-15 | $17.27M derived: sum of 3 quarters · filed 2022-03-15 | $20.95M 10-K · filed 2022-03-15 |
| 2019-09-30 | $4.91M 10-Q · filed 2020-11-06 | $9.23M derived: sum of 2 quarters · filed 2020-11-06 | $12.91M 10-Q · filed 2020-11-06 | $17.30M derived: sum of 4 quarters · filed 2021-03-16 |
| 2019-06-30 | $4.32M 10-Q · filed 2020-08-11 | $8.00M 10-Q · filed 2020-08-11 | $12.39M derived: sum of 3 quarters · filed 2021-03-16 | $14.70M derived: sum of 4 quarters · filed 2021-03-16 |
| 2019-03-31 | $3.68M 10-Q · filed 2020-05-15 | $8.07M derived: sum of 2 quarters · filed 2021-03-16 | $10.38M derived: sum of 3 quarters · filed 2021-03-16 | |
| 2018-12-31 | $4.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $6.70M derived: sum of 2 quarters · filed 2021-03-16 | $14.19M 10-K · filed 2021-03-16 | |
| 2018-09-30 | $2.31M 10-Q · filed 2019-11-14 | $9.80M 10-Q · filed 2019-11-14 | ||
| 2017-12-31 | $13.39M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |